SCHEMBL10244313

SCHEMBL10244313

CCN(CCNC(=O)OC)C(C)c1cnn(CC)c1C

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
HPGD P15428 3/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
RAB9A P51151 3/20 0.33
NPC1 O15118 1/20 0.33
PIK3CD O00329 1/20 0.32
PIK3R1 P27986 1/20 0.32
PIK3CA P42336 1/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
EPHX1 P07099 1/20 0.32
HTT P42858 2/20 0.31
PDE4B Q07343 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243922 0.78 RAB9A (0.35) HPGDSMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL10244359 0.77 ALDH1A1 (0.41) LMNAHPGDSMN1; SMN2KMT2ARAB9A
SCHEMBL10244354 0.77 MTNR1B (0.32) KMT2AMEN1RAB9AALDH1A1CYP1A2
SCHEMBL334652 0.76 HTT (0.34) LMNAALDH1A1HTT
SCHEMBL10243454 0.75 KDM4E (0.37) LMNAHPGDPOLB
SCHEMBL10243931 0.74 CYP2D6 (0.33) LMNAHPGDSMN1; SMN2KMT2AMEN1
SCHEMBL10243549 0.73 TMEM97 (0.34) LMNASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL10243634 0.72 TSHR (0.40) HPGDPOLBALDH1A1CYP2C19TSHR
SCHEMBL10243117 0.72 L3MBTL1 (0.41) HPGDKMT2AMEN1POLBALDH1A1
SCHEMBL10243567 0.72 TAS1R3 (0.34) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 LMNA 1467/4885HPGD 556/4885SMN1; SMN2 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.